Pentostatin (Nipent) — Clinical FAQs

Question 1

What is Pentostatin FDA-approved to treat?

Accepted Answer

Pentostatin is FDA-approved for the following oncology indications: 1. Hairy cell leukemia (HCL) — untreated and alpha-interferon-refractory active disease; single-agent pentostatin achieves complete response in approximately 75–85% of patients with durable long-term remissions (Nipent; FDA approved 1991).

Question 2

How does Pentostatin work (mechanism of action)?

Accepted Answer

Pentostatin (2'-deoxycoformycin) is a purine analog fermentation product of Streptomyces antibioticus that acts as an extremely potent, essentially irreversible transition-state inhibitor of adenosine deaminase (ADA) — the enzyme that deaminates adenosine and deoxyadenosine to inosine and deoxyinosine. Lymphoid cells have the highest ADA activity of any tissue, making them uniquely vulnerable. ADA inhibition causes intracellular accumulation of deoxyadenosine and its phosphorylated metabolite deoxyadenosine triphosphate (dATP), which allosterically inhibits ribonucleotide reductase, depleting the deoxynucleotide pools required for DNA synthesis and repair. Accumulated dATP and deoxyadenosine also promote DNA strand breaks, inhibit S-adenosylhomocysteine hydrolase (impairing methylation reactions), and trigger apoptosis. Like cladribine, pentostatin is cytotoxic to both dividing and resting lymphocytes, accounting for its high activity in indolent lymphoid malignancies with low proliferative fractions — most notably hairy cell leukemia. The mechanistic parallel to inherited ADA deficiency (which causes severe combined immunodeficiency) explains the profound and sustained T-cell lymphopenia produced by therapy.

Question 3

How is Pentostatin administered?

Accepted Answer

Pentostatin is administered Intravenous (IV). Hairy cell leukemia: 4 mg/m² by IV bolus or short infusion every other week (once every 14 days) until maximal response — typically continued for 1–2 doses beyond documented complete response, most patients requiring treatment for approximately 6 months.

Question 4

What are the most common side effects of Pentostatin?

Accepted Answer

The most commonly reported side effects of Pentostatin (≥10% incidence) include: Nausea and vomiting (22–53%), Fever / pyrexia (42–46%), Fatigue / malaise (29–42%), Rash and other skin eruptions (26–43%), Leukopenia / neutropenia (grade 3/4 common during early cycles) and others (14 total). Consult your oncologist for complete prescribing information.

Question 5

Is Pentostatin safe during pregnancy?

Accepted Answer

Pentostatin pregnancy safety: Can cause fetal harm. Pentostatin is embryotoxic and teratogenic in animal studies. Avoid during pregnancy; females of reproductive potential should use effective contraception during therapy, and males with female partners of reproductive potential should also use contraception. Breastfeeding is not recommended during and after therapy.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Pentostatin — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms